• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.

作者信息

Pettengell R, Crowther D

机构信息

CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.

出版信息

Ann Oncol. 1994;5 Suppl 2:133-41. doi: 10.1093/annonc/5.suppl_2.s134.

DOI:10.1093/annonc/5.suppl_2.s134
PMID:7911317
Abstract

Here we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade non-Hodgkin's lymphoma. The results of retrospective analyses and prospective studies support this proposition but confirmatory studies are required. We discuss the role of haemopoietic growth factors and mobilized peripheral blood progenitor cells to increase dose intensity. Studies using these modalities will enable the importance of dose intensity to be tested.

摘要

相似文献

1
Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
Ann Oncol. 1994;5 Suppl 2:133-41. doi: 10.1093/annonc/5.suppl_2.s134.
2
Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.造血生长因子在非霍奇金淋巴瘤治疗中剂量强化及疗效方面作用的批判性综述
Ann Oncol. 1994;5 Suppl 2:121-2. doi: 10.1093/annonc/5.suppl_2.s121.
3
[High-dose chemotherapy with bone marrow transplantation in recurrent or refractory NHL].
Sangre (Barc). 1993 Dec;38(6):473-80.
4
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.低级别非霍奇金淋巴瘤的高剂量疗法与外周血祖细胞移植
Bone Marrow Transplant. 1996 Feb;17(2):149-55.
5
High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.大剂量化疗联合自体干细胞支持治疗乳腺癌：纪念斯隆凯特琳癌症中心/贝斯以色列女执事医疗中心经验综述
J Hematother. 1993 Winter;2(4):507-11. doi: 10.1089/scd.1.1993.2.507.
6
Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.高剂量环磷酰胺、依托泊苷和顺铂序贯自体骨髓或外周血干细胞移植治疗预后不良的霍奇金淋巴瘤或非霍奇金淋巴瘤的I/II期研究
Bone Marrow Transplant. 1993 Oct;12(4):337-45.
7
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.大剂量化疗及外周血祖细胞移植治疗高级别非霍奇金淋巴瘤后细胞免疫功能恢复的时间进程。
Bone Marrow Transplant. 1995 Jun;15(6):901-6.
8
Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.剂量强度在神经肿瘤学临床试验中的重要性：血脑屏障破坏联盟第六届年会总结报告
Neuro Oncol. 2001 Jan;3(1):46-54. doi: 10.1093/neuonc/3.1.46.
9
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.采用环磷酰胺、卡莫司汀和依托泊苷对中高级别非霍奇金淋巴瘤进行自体移植治疗结果的预后因素
J Clin Oncol. 1993 Jun;11(6):1085-91. doi: 10.1200/JCO.1993.11.6.1085.
10
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.异环磷酰胺、依托泊苷、阿糖胞苷和地塞米松作为挽救治疗，随后进行大剂量环磷酰胺、美法仑和依托泊苷联合自体外周血干细胞移植用于复发或难治性淋巴瘤。
Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x.

引用本文的文献

1
Current guidelines for the management of aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤的当前管理指南。
Drugs. 1997 Jun;53(6):957-72. doi: 10.2165/00003495-199753060-00005.